Daiichi Sankyo Advances Breast Cancer Portfolio Expansion with ENHERTU approaval in Japan and DATROWAY's positive study

Daiichi Sankyo has made significant strides in oncology research and care, announcing several developments in the first week of October.

The company filed for regulatory approval of Enhertu as a first-line therapy for HER2-positive metastatic breast cancer, combining it with pertuzumab to target aggressive, treatment-resistant tumors.

In the U.S., the FDA accepted a supplemental application for a unique regimen offering Enhertu followed by THP before surgery, aiming to improve outcomes for early-stage, high-risk patients.

Simultaneously, fresh clinical trial results for Datroway - a therapy targeting metastatic triple-negative breast cancer - were published from the TROPION-Breast02 Phase 3 study. The drug demonstrated meaningful improvements in patient survival, especially for those ineligible for immunotherapy-based approaches.

Daiichi Sankyo’s made a decision to open a new research institute in San Diego underscore the company’s commitment to advancing innovative solutions. The institute will act as a hub for collaboration between biotechnology startups, academic researchers, and industry leaders, accelerating breakthroughs across oncology and beyond.

Corporate responsibility and sustainability feature prominently in Daiichi Sankyo’s October agenda. The company expanded environmental and humanitarian projects alongside its scientific progress, aiming to balance medical innovation with ethical leadership in global healthcare.